Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal ...
Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic ...
Upcoming oral presentation for the ALLOHA TM Phase 1 heme trial at the ... undergoing allogeneic HCT (the ALLOHA TM trial, NCT05473910). Plans to open expansion cohorts at the proposed recommended ...
today announced that new data from the company’s open-label Phase 2 CLOVER-WaM study of iopofosine I 131 as a potential treatment for Waldenstrom’s macroglobulinemia (WM) will be highlighted in an ...
Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Greetings, and welcome to the Acurx Pharmaceuticals, Inc. Third ...
Alumis' lead clinical candidate, ESK-001, is a potent, highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor that reduces signaling through several cytokine receptors including receptors for ...
Q3 2024 Earnings Call Transcript November 7, 2024 Geron Corporation beats earnings expectations. Reported EPS is $-0.04, ...
Angela Todd plans to present a talk on called Hidden Stories: Orphanages, Asylums and Magdalene Laundries from 6:30-8 p.m. Thursday, Nov. 21, at Norway Memorial Library at 258 Main St. Whether it came ...
The International Court of Justice has released the detailed schedule for oral arguments in its advisory opinion on the Obligations of States in respect of Climate Change ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback